ライフサイエンスコーパス: convalescent sera

1 titers increased by >/=4-fold in those with convalescent sera.

2 potential of anti-GlcCer antibodies found in convalescent sera.

3 munoglobulin G antibodies to OMP B1 in their convalescent sera.

4 candidate antigens were assayed on acute and convalescent sera.

5 ly, versus 285 (196-413) IU ml(-1) for human convalescent sera.

6 y explaining its decreased neutralization by convalescent sera.

7 hers (e.g., E484K) escaped neutralization by convalescent sera.

8 n neutralization by vaccine sera compared to convalescent sera.

9 cited by these two vaccines in comparison to convalescent sera.

10 acute sera (1-11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurologi

11 The findings suggest that convalescent sera alone is not sufficient for providing

12 ape variants from human viruses treated with convalescent sera and from mice that had been previously

13 antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the

14 e Omicron BA.1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal antibodies that are eff

15 binding domain or N-terminal domain and most convalescent sera and mRNA vaccine-induced immune sera s

16 Convalescent sera and sera from other streptococcal dise

17 de arrays showed a strong difference between convalescent sera and vaccine-elicited sera.

18 unoglobulin International Standard, COVID-19 convalescent sera, and mRNA-1273 vaccinee sera.

19 resistance to neutralization by vaccinee and convalescent sera are driving a search for monoclonal an

20 zing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput f

21 bodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donor

22 acaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9.

23 Convalescent sera displayed limited carbohydrate blockin

24 Convalescent sera displayed strong homologous blocking,

25 responses exceeded those seen in a panel of convalescent sera for both age groups.

26 Convalescent sera from 20 cholera patients infected with

27 ps the site IV sequence reacted with all the convalescent sera from 42 SARS patient, but none of the

28 onses, were assessed by Luminex in acute and convalescent sera from 91 EM patients, in serum and syno

29 ic antibody titers 3-24x as high as those in convalescent sera from a panel of COVID-19 patients and

30 Convalescent sera from cholera patients had a mean vibri

31 evels of neutralizing antibody than found in convalescent sera from COVID-19 patients and a strong Th

32 t the recombinant E. canis p120 reacted with convalescent sera from dogs with canine ehrlichiosis.

33 Here, we test >50 convalescent sera from Egyptian rousette bats (ERBs) exp

34 inated with 2, 4, 6, 8, or 12 mug CVnCoV and convalescent sera from hospitalized patients were analyz

35 cinated with 2, 4, 6, 8, or 12 ug CVnCoV and convalescent sera from hospitalized patients were analyz

36 e-linked immunosorbent assays of antibody in convalescent sera from mares naturally infected with L.

37 closely related viruses, we tested acute and convalescent sera from nine Thai patients with PCR-confi

38 Human convalescent sera from patients infected with B. abortus

39 nding domain (RBD) monoclonal antibodies and convalescent sera from people infected with either form

40 ng the entire S protein sequence against the convalescent sera from SARS patients and antisera from s

41 , Moderna, or Johnson & Johnson vaccines and convalescent sera from unvaccinated COVID-19 survivors h

42 BNT162b2-elicited sera and convalescent sera have a higher titer of spike-RBD-speci

43 infectivity and decreased neutralization by convalescent sera in vitro.

44 opharyngeal (OP) swabs (n = 1558), acute and convalescent sera (n = 568), and expectorated sputum (n

45 ce of antibodies directed to the ACE2IS from convalescent sera of 94 COVID-19-positive patients.

46 ry to inhibition by neutralizing antibody or convalescent sera of COVID-19 patients.

47 titre ratios 4-8-fold higher than for human convalescent sera (P < 0.01), and high IFNgamma spot-for

48 Analyses of convalescent sera provide unique insights into antibody

49 c IgM antibodies are responsible for much of convalescent sera's neutralizing capacity, all available

50 by screening the genomic library with swine convalescent sera showing that P102 is expressed in vivo

51 The neutralization potency of convalescent sera strongly correlates to IgG titers agai

52 One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals trea

53 by incubating them with human and/or ferret convalescent sera to human H1N1 and H3N2 viruses.

54 NPS, saliva, sputa, and acute/convalescent sera were collected and tested.

55 y 84 from 10 outbreaks, as well as acute and convalescent sera were collected.

56 The major antigens recognized by murine convalescent sera were F1, V antigen, YopH, YopM, YopD,

57 he SARS-CoV-2 neutralization titers of human convalescent sera were relatively consistent across all

58 ed higher neutralizing antibodies than human convalescent sera, with strong T-cell responses.